US lawmakers are pressing the Pentagon to speed up the mass production and deployment of synthetic blood critical for traumatic injuries on the battlefield as Congress seeks to shore up the US biotechnology field to parry China’s rapid developments.
Congress and the Pentagon are investing in the emerging biotechnology field as a critical driver of national security. The National Security Commission on Emerging Biotechnology has called on the US government to spend at least $15 billion over the next five years to unlock private capital and investment in the sector to blunt China’s rapid surge in the field.
The Defense ...